I had $BIDU at $185 as a trade during the Archegos blow up & sold a couple days later near $220~

I’ve heard good things about $JD but not as informed on it at the moment & near fully invested so not much to throw into a new position 🤷🏼‍♂️

"By creating the concept that data is a factor of production, China Inc. has formalised and legislated the stance that data itself is valuable rather than the algorithms it helps train.

The Chinese leadership has subtly but deftly implied that data's value to a nation is underpriced and currently subjected to market distortions."

I think China's making money moves in the area of data. Read about it

$JD Health and $BABA AliHealth

$JD Health and $BABA Ali Health are $JD and $BABA's newest competition ground and the two biggest online medical platforms in China . Here is a thread on the things you need to know for $JD health and $Ali health.

Let’s get started! 👇👇

1. Problem
China have MANY medical problems. These include: poor structure of the Chinese medical system, inadequate/unequal resources, long waiting time, expensive medical services, sub-par medical quality and insufficient or unskilled medical staff.

2. Long waiting time
It is very inconvenient to visit a doctor in China unless you go to expensive private ones. There is not a clear distinction between a GP and a specialist, causing many elderlies, to crowd the hospital even when they only have a small medical issue.

2.1 A typical hospital visit in China may take up to 2-3 hours, half a day, or even a full day. You can basically image a Chinese hospital is like your favorite next door grocery stores constantly at 120%-200% capacity.

3. Medical Expenditure
Although the Chinese medical system has been improving, it is still unorganised and inefficient, causing medical services/medicine to be ‘expensive’, especially to low-income earners in China. Medical service is more expensive in China than the US % wise.

BABA:

*Slowing revenue growth/maturing e-com pen; rising competition and falling market share.
*40% decline in core profitability in 3Q21.
*Run-rate core P/E probably about 40x post SBC with further significant declines possible.
*Regulatory risks/headwinds.
*Still over-owned.

I've been arguing for a while now people have been using inappropriately low forward P/E multiples for BABA, often arguing it's on <20x 2021, excluding substantial SBC and failing to account the earnings risks & reasons why the stock has been going down in the first place.

On the 19th Sept. 2014 $BABA opened at 92.70$ at the NYSE. Today it has 35.8x the revenue and 35.6x the net income.

The stock was lower yesterday at 90.82$

Sometimes the stock market is widely irrational.

Ofc I don't know for sure but this can be the home run bet for Charlie.

@LeviathanCapit1 @BuyandHoldd Okay nice